Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Amgen Biotech Experience celebrates reaching 1 million students worldwide
Since its establishment in 1990, the ABE program has now reached over 1 million students across 16 countries, helping to ...
Yahoo1d
Wide Trading Range For Amgen Stock Makes This Option Shine
Amgen posted earnings that were better than expected last month. Because Amgen stock has heavy institutional ownership, ...
Seeking Alpha4d
Amgen: Checks All The Wrong Boxes
In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
STAT4d
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Amgen’s stock closes off lows to avoid worst day in 24 years as weight-loss-drug data underwhelms
Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting ...
Eli Lilly and Novo Nordisk’s obesity moat just got stronger
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...